AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A ~~platelet increasing agent~~ pharmaceutical composition comprising a 2-acylaminothiazole derivative represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient**[[.]]**



(I)

~~[Symbols in the formula have the following meanings.~~ wherein

~~A: a lower alkylene~~ is methylene;

R^1**[[:]]** is a group represented by the formula (II), or cyclic amino which may be substituted**[[.]]**



(II)

~~[Symbols in the formula have the following meanings.~~ wherein

R^{11}**[[**: H**]]** is a hydrogen atom, a lower alkyl which may be substituted, or a cycloalkyl which may be substituted**[[.]]** such that when ~~When~~ A represents methylene, R^{11} may be present as methylene which is bridged to thienyl or phenyl represented by R^2**[[.]]** or when ~~When~~ A represents methylene, R^{11} may be present as a lower alkylene

which may be substituted and which forms a ring closed at the methylene represented by A**[[.]]** ; and

R^{12}**[[:]]** is a lower alkyl, a cycloalkyl or a non-aromatic heterocycle, each of which may be substituted**[[.]]]**;

R^2**[[:]]** is thienyl or phenyl, each of which ~~may be~~ is substituted with one or more groups selected from the group consisting, of a lower alkyl which may be substituted with one or more halogens, and a halogen; and **[[.]]**

R^3**[[:]]** is an aromatic heterocycle, an aryl or cyclic amino, each of which may be substituted.~~]~~

2. (Canceled)

3. (Canceled)

4. (Currently Amended) The pharmaceutical composition according to ~~any of claims~~ claim 1 ~~to 3~~, which is a thrombocytopenia treating agent.

5. (Currently Amended) The pharmaceutical composition according to ~~any of claims~~ claim 1 ~~to 3~~, which is a c-Mpl ligand.

6. (Currently Amended) A ~~2-acylaminothiazole derivative represented by the~~ compound of formula (III) or a pharmaceutically acceptable salt thereof**[[.]]**



(III)

~~[Symbols in the formula have the following meanings.~~ wherein

B is a lower alkylene; ~~: a group represented by A according to claim 1.~~

R^4 is a group represented by the formula (II), or cyclic amino which may be substituted



(II)

wherein

R^{11} is a hydrogen atom, a lower alkyl which may be substituted, or a cycloalkyl which may be substituted such that when B represents methylene, R^{11} may be present as methylene which is bridged to thienyl or phenyl represented by R^5 or when B represents methylene, R^{11} may be present as a lower alkylene which may be substituted and which forms a ring closed at the methylene represented by B; and

R^{12} is a lower alkyl, a cycloalkyl or a non-aromatic heterocycle, each of which may be substituted;~~: a group represented by R^4 according to claim 1.~~

R^5 is thienyl or phenyl, each of which may be substituted; and ~~: a group represented by R^2 according to claim 1.~~

R^6~~: a group represented by R^3 according to claim 1,~~ is an aromatic heterocycle, an aryl or cyclic amino, each of which may be substituted provided that unsubstituted phenyl and indole which may be substituted are excluded.~~]~~

7. (Currently Amended) The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein B is methylene.

8. (Currently Amended) The compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R^5 is thienyl or phenyl, each of which is substituted with one or more groups selected from the group consisting of a lower alkyl which may be substituted with one or more halogens, and a halogen.

9. (Currently Amended) The compound according to claim 8 or a pharmaceutically acceptable salt thereof, wherein R^6 is pyridyl which may be substituted, or phenyl which is substituted.

10. (Currently Amended) The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein R^6 is pyridin-3-yl whose 5-position is substituted with a group selected from the group consisting of chloro and fluoro, and whose 6-position is substituted, or phenyl whose 3-position is substituted with a group selected from the group consisting of chloro and fluoro, whose 5-position is 5 substituted with a group selected from the member consisting of -H, chloro and fluoro, and whose 4-position is substituted.

11. (Currently Amended) ~~Among the compounds according to~~ The compound of claim 6, wherein the compound is

1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-pyridy1)piperidine-4-carboxylic acid,

1- (5-([5-{ (butyl (methyl) amino]methyl}-4- (4-chlorothiophen-2-yl)thiazol-2-yl]carbamoyl}-3-chloro-2-pyridyl) piperidine-4-carboxylic acid,

1-{5-[(4-(4-chlorothiophen-2-yl)-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}thiazol-2-yl)carbamoyl]-3-fluoro-2-pyridy1)piperidin-4-carboxylic acid,

1-{ 3-chloro-5- [(4- (4-chlorothiophen-2-yl) -5-{ [(2S) -2- methylpyrrolidin-1-yl] methyl} thiazol-2-yl) carbamoyl]-2-pyridyl} piperidine-4-carboxylic acid,

1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(dimethylaminomethyl)thiazol-2-yl] carbamoyl}-2-pyridyl) piperidine-4-carboxylic acid,

1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{ [isopropyl (methyl) amino]methyl} thiazol-2-yl) carbamoyl] -2-pyridyl}piperidine-4-carboxylic acid,

4-[{3-chloro-5-[(4-(4-chlorothiophen-2-y1)-5-[isopropyl (methyl) amino] methyl} thiazol-2-yl) carbamoyl] -2-pyridyl} (methyl) amino] butyric acid,

1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{ [(3S)-3-methylpyrrolidin-1-yl]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl} piperidine-4-carboxylic acid,

1-{3-chloro-5- [(4 - (4-chlorothiophen-2-yl) -5-{ [[(2S) -2-methoxypropyl] (methyl) amino]methyl} thiazol-2-yl) carbamoyl] -2-pyridyl) piperidine-4-carboxylic acid,

N- [5- { [butyl (methyl) arnino]methyl} -4- (4-chlorothiophen-2-yl) thiazol-2-yl] -5-chloro-6- [(3-hydroxypropyl)amino]nicotinamide,

N- [5- { [butyl (methyl) amino]methyl} -4- (4-chlorothiophen-2-yl)thiazol-2-yl]-5-chloro-6-(3-oxopiperazin-1-yl) nicotinamide or

N- [5- { [butyl (methyl) amino] methyl } -4- (4-chlorothiophen-2-yl)thiazol-2-yl]-5-chloro-6-[4-(hydroxymethyl)piperidino] nicotinamide, or

a pharmaceutically acceptable salt thereof.

12. (Currently Amended) A pharmaceutical composition comprising the compound according to any one of claims 6 to 11 as an active ingredient.

13. (Original) The pharmaceutical composition according to claim 12, which is a platelet increasing agent.

14. (Original) The pharmaceutical composition according to claim 12, which is a thrombocytopenia treating agent.

15. (Original) The pharmaceutical composition according to claim 12, which is a c-Mpl ligand.

16. (New) A method of increasing platelets in a patient comprising administering to the patient a pharmaceutical composition comprising a 2-acylaminothiazole derivative represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient



(I)

wherein

A: a lower alkylene;

R^1 is a group represented by the formula (II), or cyclic amino which may be substituted



(II)

wherein

R^{11} is a hydrogen atom, a lower alkyl which may be substituted, or a cycloalkyl which may be substituted such that when A represents methylene, R^{11} may be present as methylene which is bridged to thienyl or phenyl represented by R^2 or when A represents

methylene, R^{11} may be present as a lower alkylene which may be substituted and which forms a ring closed at the methylene represented by A; and

R^{12} is a lower alkyl, a cycloalkyl or a non-aromatic heterocycle, each of which may be substituted;

R^2 is thienyl or phenyl, each of which may be is substituted; and

R^3 is an aromatic heterocycle, an aryl or cyclic amino, each of which may be substituted.

17. (New) The method according to claim 16, wherein A is methylene.

18. (New) The method according to claim 17, wherein R^2 is thienyl or phenyl, each of which is substituted with one or more groups selected from the group consisting, of a lower alkyl which may be substituted with one or more halogens, and a halogen.

19. (New) The method according to claim 16, wherein the pharmaceutical composition is administered orally in a daily amount of 0.0001 mg/kg body weight to 50 mg/kg body weight, 0.001 mg/kg body weight to 10 mg/kg body weight, or 0.01 mg/kg body weight to 1 mg/kg body weight.

20. (New) The method according to claim 19, wherein the daily amount is administered in one, two, three, or four doses.

21. (New) The method according to claim 16, wherein the pharmaceutical composition is administered intravenously in a daily amount of 0.0001 mg/kg body weight to 1 mg/kg body weight or 0.0001 mg/kg body weight to 0.1 mg/kg body weight.

22. (New) A method of treating thrombocytopenia in a patient comprising administering to the patient a pharmaceutical composition comprising a 2-acylaminothiazole derivative represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient



(I)

wherein

A: a lower alkylene;

R^1 is a group represented by the formula (II), or cyclic amino which may be substituted



(II)

wherein

R^{11} is a hydrogen atom, a lower alkyl which may be substituted, or a cycloalkyl which may be substituted such that when A represents methylene, R^{11} may be present as methylene which is bridged to thienyl or phenyl represented by R^2 or when A represents methylene, R^{11} may be present as a lower alkylene which may be substituted and which forms a ring closed at the methylene represented by A; and

R^{12} is a lower alkyl, a cycloalkyl or a non-aromatic heterocycle, each of which may be substituted;

R^2 is thienyl or phenyl, each of which may be is substituted; and

R^3 is an aromatic heterocycle, an aryl or cyclic amino, each of which may be substituted.

23. (New) The method according to claim 22, wherein A is methylene.

24. (New) The method according to claim 23, wherein R^2 is thienyl or phenyl, each of which is substituted with one or more groups selected from the group consisting, of a lower alkyl which may be substituted with one or more halogens, and a halogen.

25. (New) The method according to claim 22, wherein the pharmaceutical composition is administered orally in a daily amount of 0.0001 mg/kg body weight to 50 mg/kg body weight, 0.001 mg/kg body weight to 10 mg/kg body weight, or 0.01 mg/kg body weight to 1 mg/kg body weight.

26. (New) The method according to claim 25, wherein the daily amount is administered in one, two, three, or four doses.

27. (New) The method according to claim 22, wherein the pharmaceutical composition is administered intravenously in a daily amount of 0.0001 mg/kg body weight to 1 mg/kg body weight or 0.0001 mg/kg body weight to 0.1 mg/kg body weight.

28. (New) The method according to claim 22, wherein the thrombocytopenia is caused by one or more of anemia, myelodysplastic syndrome, chemotherapy, radiotherapy, idiopathic thrombocytopenic purpura, hepatic diseases, and human immunodeficiency virus (HIV).

29. (New) A method of regulating c-Mpl activity comprising administering a c-Mpl ligand to a patient, wherein the c-Mpl ligand comprises a 2-acylaminothiazole derivative represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient



(I)

wherein

A: a lower alkylene;

R^1 is a group represented by the formula (II), or cyclic amino which may be substituted



(II)

wherein

R^{11} is a hydrogen atom, a lower alkyl which may be substituted, or a cycloalkyl which may be substituted such that when A represents methylene, R^{11} may be present as methylene which is bridged to thienyl or phenyl represented by R^2 or when A represents methylene, R^{11} may be present as a lower alkylene which may be substituted and which forms a ring closed at the methylene represented by A; and

R^{12} is a lower alkyl, a cycloalkyl or a non-aromatic heterocycle, each of which may be substituted;

R^2 is thienyl or phenyl, each of which may be is substituted; and

R^3 is an aromatic heterocycle, an aryl or cyclic amino, each of which may be substituted.

30. (New) The method according to claim 29, wherein A is methylene.

31. (New) The method according to claim 30, wherein R^2 is thienyl or phenyl, each of which is substituted with one or more groups selected from the group consisting, of a lower alkyl which may be substituted with one or more halogens, and a halogen.

32. (New) The method according to claim 29, wherein the pharmaceutical composition is administered orally in a daily amount of 0.0001 mg/kg body weight to 50 mg/kg body weight, 0.001 mg/kg body weight to 10 mg/kg body weight, or 0.01 mg/kg body weight to 1 mg/kg body weight.

33. (New) The method according to claim 32, wherein the daily amount is administered in one, two, three, or four doses.

34. (New) The method according to claim 29, wherein the pharmaceutical composition is administered intravenously in a daily amount of 0.0001 mg/kg body weight to 1 mg/kg body weight or 0.0001 mg/kg body weight to 0.1 mg/kg body weight.

.